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A 58-year-old nonsmoker female was referred for evaluation of chronic cough of 13 months duration. After an initial work-
up, the patient was diagnosed to have chronic cough due to eosinophilic bronchitis. The diagnostic work-up for eosinophilic
bronchitis and bronchial biopsy is discussed. Eosinophilic bronchitis is diﬀerentiated from asthma. In addition, the patient
developed dyspnea, ﬂushing, and wheezing after the administration of adenosine during a cardiac stress test in spite of a negative
methacholine challenge. This indirect stimulus of airway hyperresponsiveness suggests the possible involvement of mast cells in
eosinophilic bronchitis.
Copyright © 2009 Rodrigo Cartin-Ceba et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Eosinophilic bronchitis is an uncommon cause of chronic
cough in the general practice; however, this entity has been
found to be present in 10–20% of patients referred for an
investigation by a specialist [1], and recent studies suggest
that it can be present in up to 33% of nonsmokers patients
referred for chronic cough evaluation [2]. Eosinophilic
bronchitis was originally described by Gibson et al. in 1989
[3] and has subsequently been recognized as an important
cause of chronic cough. We present the case of a 58-
year-old female with chronic cough due to eosinophilic
bronchitis complicated by dyspnea, ﬂushing, and wheezing
after administration of adenosine for a sestamibi cardiac
stress test.
2.CaseReport
A 58-year-old post menopausal nonsmoker Caucasian
female was evaluated for chronic cough of 13 months
duration. The patient has a past medical history signiﬁcant
for hyperlipidemia, and obstructive sleep apnea. The cough
was described as a dry cough and was severe enough
to cause her to gag and vomit. She reported frequent
nighttime awakenings due to cough. Initial work-up at
another facility was reported as normal pulmonary function
tests, negative methacholine challenge test, normal chest
radiogram, normal chest and sinus CT scans, and a normal
inspection of vocal cords, trachea, and bronchi by ﬂexible
bronchoscopy. A bronchial biopsy was performed during
the bronchoscopy and results are reviewed below. She was
prescribed an empiric one-week trial of prednisone which
resulted in near resolution of her cough. The patient was
then started on inhaled ﬂuticasone and tiotropium without a
clear diagnosis given. As a consequence, she was uncertain
about the use of the inhalers and was noncompliant. The
cough came back prompting another evaluation. The cough
was not associated with rhinorrhea, sneezing, wheezing,
dyspnea, postnasal drip, heartburn, chestpain, fever,sputum
production, hemoptysis, weight loss, or night sweats. She
denied ever having had exposure to immigrants or any travel
outside her home state. No history of ACE inhibitors intake
was noted. The patient worked with Christmas trees helping
to shear, bale, and make wreaths. She has a dog at home2 Case Reports in Medicine
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Figure 1: High power photomicrograph of bronchial wall show-
ing mucosa with thickened basal membrane (A) and numerous
submucosal eosinophils (arrow), including degranulated forms
(Hematoxylin and Eosin; 400X).
but no other pets. She has no prior history of allergies
or allergy testing. The patient did not have a history of
childhood asthma, sinusitis, GERD, hayfever or tuberculosis,
and no history of indoor hot tub. In addition, the patient
complained of bilateral sharp chest discomfort for about 10
months, associated with the cough episodes, nonradiating
and not associated with exercise, nausea, or diaphoresis.
Physical examination showed normal vital signs. There
was a perforated right tympanic membrane. Oropharynx
showed no exudates or lesions, and normal nasal mucosa
with no polyps. Lung auscultation showed normal breath
sounds, and no wheezing or crackles. The heart rhythm
was regular and auscultation evidenced no murmurs, rub,
or gallop; her abdomen was soft with no organomegaly,
extremities with no peripheral edema, and the skin showed
no cyanosis or rash. Finally, no clubbing was observed.
Diagnostic work up included a spirometry with FEV1 112%
ofpredicted,FVC111%ofpredicted,andanFEV1/FVCratio
of 81. The shape of the inspiratory and expiratory ﬂow-
volume curves was unremarkable. The diﬀusing capacity
showed a DLCO of 97% of predicted. The methacholine
challenge test showed that the PC20 was >16mg/dL (normal
bronchial responsiveness). Chest CT showed no inﬁltrates
or pleural eﬀusions, and no abnormal hilar or mediastinal
lymphadenopathy. CT scan of the sinuses showed normal
mucosal thickening and no air-ﬂuid levels. A 24-hour
esophageal pH probe of proton pump inhibitor excluded
gastroesophageal reﬂux disease. CBC showed hemoglobin
of 13.6g/dL (normal range 12–15.5g/dL), the WBC was
9.2×109/L (normal range 3.5– 10.5 ×109/L), and diﬀerential
evidenced 60% Neutrophils, 1% eosinophils, 35% lympho-
cytes, and 4% monocytes. Electrolytes including sodium,
potassium, chloride, calcium, magnesium, and phosphorus
were within normal limits. Serum creatinine and BUN were
0.8mg/dL (normal range 0.6–1.1mg/dL), and 12mg/dL
(normal range 6–21mg/dL) respectively. Serology for Bor-
detella pertussis and Respiratory Syncytial virus (RSV) were
negative. Her oral exhaled nitric oxide was elevated to 158
parts/billion (upper limit of normal <30 parts/billion). The
biopsy of the left main bronchus was reviewed and revealed
peribronchiolar chronic inﬂammation with eosinophils and
thickened basement membrane (Figure 1). Sputum exam-
ination for eosinophil was not performed. Based on the
normal spirometry, negative methacholine challenge test,
the elevated oral exhaled nitric oxide that correlates with
eosinophilic airway inﬂammation [4, 5] and bronchial
biopsy, a diagnosis of chronic cough due to eosinophilic
bronchitis was made. To exclude the possibility of a cardiac
cause of her chest discomfort, the patient underwent an
adenosine sestamibi study. During this test, she developed
sudden onset of dyspnea, ﬂushing, and bilateral wheezing
(conﬁrmed by two diﬀerent clinicians) during the adenosine
infusion and required hospitalization in the intensive care
unit, where she was successfully treated with intravenous
aminophylline.
3. Discussion
The diagnosis of eosinophilic bronchitis is usually made in
patients with chronic cough and airway eosinophilia in the
absence of dyspnea, wheezing, airﬂow limitation, and lack of
airway hyperresponsiveness measured by the methacholine
challenge test. When facing a patient with chronic cough, it
is always very important to exclude other common causes
of chronic cough such as gastroesophageal reﬂux disease,
asthma, or upper airway cough syndrome. Asthma, cough
variant asthma, and EB share many features including
chronic cough and airway eosinophilia (≥3% eosinophils in
the sputum, increased eosinophils in bronchial biopsy, or
oral exhaled nitric oxide >30 parts/billion). However, the
hyperresponsiveness provocative test with methacholine is
positive with asthma or cough variant asthma; whereas it
is negative with EB and helps to diﬀerentiate these entities
(Table 1).
Erlich described the eosinophil more than 100 years ago
and its presence in the sputum was initially recognized as
an important marker in asthma [6]. Eosinophils are closely
associated with immune responses due to the activation
of Th2 lymphocytes through the production of speciﬁc
eosinophilic growth factors such as IL-5, IL-4, and IL-13 [7].
As stated above, the main diﬀerence of EB and asthma lies in
the lack of airway hyperresponsiveness seen in EB with direct
stimuli to measure bronchial hyperresponsiveness such as
methacholine challenge test.
The histological changes described in the biopsy of EB
are seen also in asthma and cough variant asthma, and a
similar Th2 cytokine driven airway inﬂammation has been
proposed in both entities [8, 9]; however, as stated above,
airwayhyperresponsivenessandvariableairﬂowobstruction,
which are the deﬁning features of asthma, are not present
in eosinophilic bronchitis. Similar levels of IL-4 and IL-5
have been found in both asthma and eosinophilic bronchitis
[9], but recent studies showed that levels of IL-13 are
signiﬁcantly higher in asthmatic patients than patients with
eosinophilic bronchitis, who have levels of IL-13 similar to
healthy subjects [7].
The presence of elevated oral exhaled nitric oxide (eNO)
has been correlated with predominantly eosinophilic airway
inﬂammation and can be seen in both asthma and EB [4, 5].Case Reports in Medicine 3
Table 1: Comparison of clinical ﬁndings and tests between asthma, cough variant asthma, and eosinophilic bronchitis.
Wheezing Cough
Bronchoprovocation
testing (airway
hyperresponsiveness)
Eosinophils in
sputum
Exhaled oral
nitric oxide
Response to inhaled
steroids
Asthma Common
symptom
May be present Positive methacholine
challenge test
Sputum
eosinophilia
(≥3%)
>30
parts/billion Improved symptoms
Cough variant asthma Absent Always present Positive methacholine
challenge test
Sputum
eosinophilia
(≥3%)
>30
parts/billion Improved symptoms
Eosinophilic bronchitis Absent Always present Negative methacholine
challenge test
Sputum
eosinophilia
(≥3%)
>30
parts/billion Improved symptoms
Treatment with inhaled corticosteroids usually reduces the
level of eNO in both entities [5]. Eosinophilic bronchitis
responds well to treatment with inhaled corticosteroids in
the short term, with a reduction in symptoms and fall
in sputum eosinophil count [10]; however, the long-term
outcome of the disease is unclear. In a 10-year followup
study of the eight patients originally described by Gibson,
complete resolution of symptoms was the most common
outcome but a minority of patients had developed ﬁxed
airﬂow obstruction [11]. Brightling et al. have also described
a patient with eosinophilic bronchitis who developed ﬁxed
airﬂow obstruction in association with prolonged uncon-
trolled eosinophilic airway inﬂammation [1]. Others have
speculated that eosinophilic bronchitis is an early stage in
the development of an asthma phenotype [12] although
there is less evidence that evolution to more typical asthma
occurs. A more recent study of 32 patients, who were initially
diagnosed as eosinophilic bronchitis and were followed for
morethan1yearwithinhaledcorticosteroidtherapy,showed
that 3 patients developed symptoms consistent with asthma
and had a positive methacholine challenge test after an initial
negative one, 5 patients developed ﬁxed airﬂow obstruction
and one patient remained symptom free after stopping the
therapy; the remaining patients presented ongoing milder
symptoms [13].
Our patient developed symptoms and signs suggestive
of airway hyperresponsiveness after the administration of
intravenous adenosine for the cardiac stress test that was
ordered to evaluate her atypical chest pain. Adenosine type
2 receptors are found in the mast cells and when stimulated
can potentiate the histamine release from these cells and
therefore precipitate bronchoconstriction [14]. Interestingly,
histamine and prostaglandin D2 concentrations have been
found to be increased in EB when compared with asthma,
suggesting that the activation of mast cells in the superﬁcial
airway mucosa may diﬀer in these two diseases [15].
Patientswitheosinophilicbronchitisshowvariablybronchial
hyperresponsiveness to nebulized adenosine with 6 out of 9
being negative [16]. Response to indirect stimuli of airway
hyperresponsiveness has not been well described in EB.
PatientswithEBdonotmanifestairwayhyperresponsiveness
with direct stimuli that is, methacholine. Adenosine stress
test for cardiac ischemia should be reconsidered in patients
with chronic cough if eosinophilic bronchitis is suspected
based on our report. This is the ﬁrst description of symp-
toms and signs suggestive of airway hyperresponsiveness
associated with adenosine injection in a patient with known
eosinophilic bronchitis.
4. Conclusion
Eosinophilic bronchitis is a common cause of chronic cough
in referral centers. It shares similarities with asthma such as
increased eosinophils in the airways, increased IL-4 and IL-5,
and improvement of symptoms with inhaled corticosteroids;
however,eosinophilicbronchitisdiﬀersfromasthmabecause
it presents with normal pulmonary function and normal
airway responsiveness. We described the ﬁrst case of airway
hyperresponsiveness after systemic administration of adeno-
sine in a patient with eosinophilic bronchitis presenting as
chronic cough.
References
[1] C. E. Brightling, R. Ward, K. L. Goh, A. J. Wardlaw, and I.
D. Pavord, “Eosinophilic bronchitis is an important cause of
chronic cough,” American Journal of Respiratory and Critical
Care Medicine, vol. 160, no. 2, pp. 406–410, 1999.
[2] S. ¨ OA y i k ,¨ O. K. Basglu, M. Erd´ ınc ¸, S. Bor, A. Veral, and C.
B´ ılgen, “Eosinophilic bronchitis as a cause of chronic cough,”
Respiratory Medicine, vol. 97, no. 6, pp. 695–701, 2003.
[3] P .G.Gibson,J .Dolovich,J .Denburg,E.H.Ramsdale,andF .E.
Hargreave, “Chronic cough: eosinophilic bronchitis without
asthma,” The Lancet, vol. 1, no. 8651, pp. 1346–1348, 1989.
[4] G. S. Berlyne, K. Parameswaran, D. Kamada, A. Efthimiadis,
andF.E.Hargreave,“Acomparisonofexhalednitricoxideand
induced sputum as markers of airway inﬂammation,” Journal
of Allergy and Clinical Immunology, vol. 106, no. 4, pp. 638–
644, 2000.
[5] S.A.KharitonovandP.J.Barnes,“Exhaledbiomarkers,”Chest,
vol. 130, no. 5, pp. 1541–1546, 2006.
[6] A. Gollash, “Zur des asthmatischen sputums,” Fortschritte der
Medizin, vol. 7, pp. 361–365, 1889.
[7] S.-W. Park, H. K. Jangm, M. H. An, et al., “Interleukin-13 and
interleukin-5 in induced sputum of eosinophilic bronchitis:
comparison with asthma,” Chest, vol. 128, no. 4, pp. 1921–
1927, 2005.4 Case Reports in Medicine
[8] C. E. Brightling, F. A. Symon, S. S. Birring, P. Bradding, I.
D. Pavord, and A. J. Wardlaw, “TH2 cytokine expression in
bronchoalveolar lavage ﬂuid T lymphocytes and bronchial
submucosa is a feature of asthma and eosinophilic bronchitis,”
Journal of Allergy and Clinical Immunology, vol. 110, no. 6, pp.
899–905, 2002.
[9] C. E. Brightling, F. A. Symon, S. S. Birring, P. Bradding,
A. J. Wardlaw, and I. D. Pavord, “Comparison of airway
immunopathology of eosinophilic bronchitis and asthma,”
Thorax, vol. 58, no. 6, pp. 528–532, 2003.
[10] C.E.Brightling,R.Ward,A.J.Wardlaw,andI.D.Pavord,“Air-
way inﬂammation, airway responsiveness and cough before
and after inhaled budesonide in patients with eosinophilic
bronchitis,” European Respiratory Journal,v o l .1 5 ,n o .4 ,p p .
682–686, 2000.
[ 1 1 ]R .J .H a n c o x ,R .L e i g h ,M .M .K e l l y ,a n dF .E .H a r g r e a v e ,
“Eosinophilic bronchitis,” The Lancet, vol. 358, no. 9287, p.
1104, 2001.
[12] D.W.Cockcroft,“Eosinophilicbronchitisasacauseofcough,”
Chest, vol. 118, no. 1, p. 277, 2000.
[13] M. A. Berry, B. Hargadon, S. McKenna, et al., “Observational
study of the natural history of eosinophilic bronchitis,”
Clinical and Experimental Allergy, vol. 35, no. 5, pp. 598–601,
2005.
[14] J.vanSchoor,G.F.Joos,andR.A.Pauwels,“Indirectbronchial
hyperresponsiveness in asthma: mechanisms, pharmacology
and implications for clinical research,” European Respiratory
Journal, vol. 16, no. 3, pp. 514–533, 2000.
[15] S. S. Birring, M. Berry, C. E. Brightling, and I. D. Pavord,
“Eosinophilic bronchitis: clinical features, management and
pathogenesis,” American Journal of Respiratory Medicine, vol.
2, no. 2, pp. 169–173, 2003.
[16] P. G. Gibson, F. E. Hargreave, A. Girgis-Gabardo, M.
Morris, J. A. Denburg, and J. Dolovich, “Chronic cough
with eosinophilic bronchitis: examination for variable airﬂow
obstruction and response to corticosteroid,” Clinical and
Experimental Allergy, vol. 25, no. 2, pp. 127–132, 1995.